RISDIPLAM
risdiplam 5 mg tablet, 28
RISDIPLAM (15308Q)
15308Q
Manner of administration:Oral
Restriction
Indication: Pre-symptomatic spinal muscular atrophy (SMA)
Treatment phase: Continuing/maintenance treatment of pre-symptomatic spinal muscular atrophy (SMA)
with 3 copies of the SMN2 gene
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 5 | DPMQ: $25,346.62 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Evrysdi | |||||